Market capitalization | $44.44m |
Enterprise Value | $45.07m |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | negative |
EV/Sales (TTM) EV/Sales | 63.48 |
P/S ratio (TTM) P/S ratio | 62.59 |
P/B ratio (TTM) P/B ratio | 3.64 |
Revenue (TTM) Revenue | $710.00k |
EBIT (operating result TTM) EBIT | $-22.88m |
As a Free StocksGuide user, you can view scores for all 6,883 stocks worldwide.
3 Analysts have issued a Oncocyte Corporation forecast:
3 Analysts have issued a Oncocyte Corporation forecast:
Sep '24 |
+/-
%
|
||
Revenue | 0.71 0.71 |
91%
91%
|
|
Gross Profit | -1.18 -1.18 |
19%
19%
|
|
EBITDA | -22 -22 |
57%
57%
|
EBIT (Operating Income) EBIT | -23 -23 |
59%
59%
|
Net Profit | -43 -43 |
32%
32%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
OncoCyte Corp. is a molecular diagnostics company, which engages in the development and commercialization of diagnostic tests for the detection of cancer, including molecular diagnostic services to pharmaceutical customers. Its products include DetermaRx and DetermaIO. The firm also offers pharmaceutical services like multi-analyte test development and clinical trial services. The company was founded in September 2009 and is headquartered in Alameda, CA.
Head office | United States |
CEO | Joshua Riggs |
Employees | 46 |
Founded | 2009 |
Website | www.oncocyte.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.